• The New Money
  • Posts
  • Lunar Soil Excavation, New Thermoelectric Applications, and a Psychedelic Biotech Breakthrough

Lunar Soil Excavation, New Thermoelectric Applications, and a Psychedelic Biotech Breakthrough

Uncovering the world’s most exciting early stage companies. Discover what’s next.

FDA Grants Breakthrough Therapy Designation For Psychedelic Depression Drug

Cybin (NYSE:CYBN) has been granted Breakthrough Therapy designation from the FDA for their novel psychedelic molecule CYB003 for Major Depressive Disorder. Breakthrough Therapy designations from the FDA provide an expedited review pathway for future clinical trials, which can meaningfully reduce the time it takes to bring a new drug closer to final approval. Cybin also announced $150 million of new capital to fund the rest of their clinical trial development.

The New Lightweight Thermoelectric Generator For Solar And Drones

PyroDelta Energy unveiled a new lightweight thermoelectric generator that utilizes high purity tellurium. The 2.5 ounce device unlocks potential applications for extending the battery life of drones and the range of solar power deployment. First Tellurium (CSE:FTEL) owns a majority stake of PyroDelta Energy and plans to supply the tellurium necessary to begin full scale production of the thermoelectric generator.

Lunar Soil Excavation Startup Lands $18 Million

Interlune raised $18 million in a seed round, led by Seven Seven Six, the venture capital fund of Reddit co-founder Alexis Ohanian. The company has developed patent pending technology that uses small machines to excavate lunar soil and is aiming to become the first in the United States to commercialize extracting resources from the moon, starting with Helium-3.

The Sprint

The Markets: Year-To-Date

+220.0% | Bitcoin Well (TSXV:BTCW). The company is focused on disrupting Bitcoin ownership through easy self-custody via their online portal and network of Bitcoin ATMs.

+66.9% | Solana. The layer 1 blockchain ecosystem has continued to gain ground on Ethereum, innovating through hardware, real world applications, and more.

+10.3% | COMPASS Pathways (NASDAQ:CMPS). The biotechnology and drug discovery company is exploring new ways to integrate psychedelic assisted therapies.

New here? Join our community of 25,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.